Michael Lyle
Directeur Technique/Scientifique/R&D chez Welichem Biotech, Inc.
Postes actifs de Michael Lyle
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Welichem Biotech, Inc.
 Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | Directeur Technique/Scientifique/R&D | 01/12/2009 | - |
Historique de carrière de Michael Lyle
Formation de Michael Lyle
| Simon Fraser University | Doctorate Degree |
Statistiques
Internationale
| Canada | 3 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Sectorielle
| Health Technology | 2 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Welichem Biotech, Inc.
Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | Health Technology |
- Bourse
- Insiders
- Michael Lyle
- Expérience
